NASDAQ:BLUE - bluebird bio Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $60.53
  • Forecasted Upside: 84.67 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 12 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$32.78
▼ -0.05 (-0.15%)
1 month | 3 months | 12 months
Get New bluebird bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$60.53
▲ +84.67% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $60.53, with a high forecast of $93.00 and a low forecast of $27.00. The average price target represents a 84.67% upside from the last price of $32.78.

Hold

The current consensus among 18 contributing investment analysts is to hold stock in bluebird bio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 11 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 13 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 13 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 12 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021OppenheimerReiterated RatingHoldMedium
i
6/10/2021SVB LeerinkInitiated CoverageBuyMedium
i
4/21/2021BMO Capital MarketsLower Price TargetMarket Perform$35.00 ➝ $31.00Medium
i
4/19/2021Morgan StanleyLower Price TargetEqual Weight$45.00 ➝ $36.00Medium
i
3/29/2021Piper SandlerBoost Price Target$30.00 ➝ $35.00High
i
3/29/2021Jefferies Financial GroupReiterated RatingBuyHigh
i
3/29/2021SVB LeerinkBoost Price TargetOutperform$69.00 ➝ $72.00N/A
i
3/29/2021BMO Capital MarketsBoost Price TargetMarket Perform$31.00 ➝ $35.00High
i
3/28/2021OppenheimerReiterated RatingHoldHigh
i
3/14/2021SVB LeerinkReiterated RatingBuyMedium
i
3/10/2021Stifel NicolausBoost Price Target$26.00 ➝ $31.00Medium
i
3/10/2021MizuhoUpgradeNeutral ➝ Buy$34.00 ➝ $69.00High
i
3/2/2021Morgan StanleyLower Price TargetEqual Weight$50.00 ➝ $45.00Medium
i
2/24/2021BarclaysLower Price TargetEqual Weight$31.00 ➝ $27.00Medium
i
2/17/2021BMO Capital MarketsBoost Price TargetMarket Perform$36.00 ➝ $56.00Low
i
2/17/2021Stifel NicolausLower Price TargetHold$48.00 ➝ $35.00Low
i
2/17/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector PerformLow
i
2/17/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$76.00 ➝ $39.00Low
i
2/16/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/16/2021Bank of AmericaDowngradeBuy ➝ NeutralLow
i
2/16/2021WedbushDowngradeOutperform ➝ NeutralLow
i
Rating by D. Nierengarten at Wedbush
2/16/2021MizuhoDowngradeBuy ➝ NeutralLow
i
2/16/2021Piper SandlerLower Price TargetNeutral$55.00 ➝ $35.00Low
i
2/16/2021William BlairDowngradeOutperform ➝ Market PerformLow
i
Rating by R. Prasad at William Blair
12/9/2020Maxim GroupDowngradeBuy ➝ HoldHigh
i
12/7/2020MizuhoReiterated RatingBuyHigh
i
11/11/2020Berenberg BankInitiated CoverageBuy$64.00Low
i
11/11/2020Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $50.00Low
i
11/6/2020WedbushLower Price TargetOutperform$81.00 ➝ $73.00Medium
i
11/5/2020Stifel NicolausDowngradeBuy ➝ Hold$77.00 ➝ $51.00Medium
i
11/5/2020BarclaysDowngradeOverweight ➝ Equal WeightHigh
i
11/5/2020Canaccord GenuityLower Price TargetBuy$118.00 ➝ $86.00High
i
11/5/2020JPMorgan Chase & Co.Lower Price TargetOverweight$140.00 ➝ $76.00High
i
11/5/2020Wells Fargo & CompanyLower Price TargetOverweight$94.00 ➝ $81.00High
i
11/5/2020SVB LeerinkLower Price TargetOutperform$133.00 ➝ $99.00High
i
11/5/2020Bank of AmericaLower Price TargetBuy$100.00 ➝ $81.00High
i
11/5/2020Royal Bank of CanadaLower Price TargetOutperform$100.00 ➝ $93.00High
i
11/5/2020OppenheimerLower Price TargetOutperform$111.00 ➝ $90.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/5/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$108.00 ➝ $56.00High
i
11/4/2020Piper SandlerLower Price TargetNeutral$70.00 ➝ $55.00High
i
11/2/2020William BlairUpgradeMarket Perform ➝ OutperformMedium
i
Rating by R. Prasad at William Blair
10/19/2020MizuhoInitiated CoverageBuy$123.00Medium
i
8/31/2020OppenheimerInitiated CoverageBuy$111.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/30/2020William BlairReiterated RatingHoldHigh
i
8/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
8/10/2020Morgan StanleyLower Price TargetEqual Weight$73.00 ➝ $68.00Medium
i
8/6/2020BMO Capital MarketsLower Price TargetOutperform$112.00 ➝ $108.00High
i
8/6/2020WedbushLower Price TargetOutperform$89.00 ➝ $81.00Medium
i
7/29/2020OppenheimerInitiated CoverageBuy$111.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
7/13/2020Bank of AmericaLower Price TargetBuy$104.00 ➝ $100.00High
i
6/12/2020SVB LeerinkBoost Price TargetOutperform$129.00 ➝ $133.00Medium
i
6/1/2020OppenheimerInitiated CoverageBuy$111.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/28/2020Morgan StanleyBoost Price TargetEqual Weight$69.00 ➝ $73.00Medium
i
5/28/2020SVB LeerinkBoost Price TargetOutperform$125.00 ➝ $129.00Low
i
5/17/2020OppenheimerInitiated CoverageBuy$111.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/13/2020BarclaysReiterated RatingBuyHigh
i
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$100.00High
i
5/12/2020Canaccord GenuityReiterated RatingBuy$118.00High
i
5/12/2020BMO Capital MarketsBoost Price TargetOutperform$107.00 ➝ $112.00High
i
5/11/2020OppenheimerInitiated CoverageBuy$122.00 ➝ $111.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/11/2020Piper SandlerLower Price TargetNeutral$75.00 ➝ $70.00High
i
4/15/2020Morgan StanleyLower Price TargetEqual Weight$92.00 ➝ $69.00Low
i
Rating by Matthew Harrison at Morgan Stanley
3/27/2020BMO Capital MarketsLower Price TargetOutperform$132.00 ➝ $107.00Low
i
3/27/2020William BlairReiterated RatingHoldMedium
i
3/26/2020Stifel NicolausUpgradeHold ➝ Buy$94.00 ➝ $70.00Low
i
Rating by Benjamin Burnett at Stifel Nicolaus
3/26/2020Piper SandlerLower Price Target$85.00 ➝ $75.00Low
i
3/26/2020Wells Fargo & CompanyReiterated RatingBuyMedium
i
2/26/2020Morgan StanleyLower Price TargetEqual Weight$100.00 ➝ $92.00Low
i
Rating by Matthew Harrison at Morgan Stanley
2/20/2020OppenheimerLower Price Target$135.00 ➝ $128.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
2/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market PerformHigh
i
2/19/2020Stifel NicolausLower Price TargetHold$96.00 ➝ $94.00High
i
Rating by Benjamin Burnett at Stifel Nicolaus
2/3/2020Bank of AmericaInitiated CoverageBuy$120.00High
i
2/3/2020Evercore ISIUpgradeIn-Line ➝ Outperform$86.00 ➝ $100.00High
i
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
12/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$135.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/10/2019William BlairReiterated RatingHoldHigh
i
Rating by Raju Prasad at William Blair
12/9/2019Wells Fargo & CompanyLower Price TargetOverweight$242.00 ➝ $160.00High
i
12/9/2019Canaccord GenuityLower Price TargetBuy$171.00 ➝ $118.00High
i
12/6/2019CowenReiterated RatingBuyLow
i
11/27/2019Evercore ISIDowngradeOutperform ➝ In-LineMedium
i
11/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$119.00Low
i
Rating by M. Foroohar at SVB Leerink LLC
11/21/2019CowenReiterated RatingBuyMedium
i
11/4/2019WedbushUpgradeNeutral ➝ Outperform$131.00 ➝ $124.00High
i
Rating by D. Nierengarten at Wedbush
11/1/2019Stifel NicolausSet Price TargetHold$96.00Low
i
Rating by Benjamin Burnett at Stifel Nicolaus
11/1/2019Morgan StanleySet Price TargetHold$104.00 ➝ $100.00Low
i
Rating by Matthew Harrison at Morgan Stanley
11/1/2019Maxim GroupReiterated RatingBuy$130.00Low
i
10/11/2019Morgan StanleyLower Price TargetEqual Weight$136.00 ➝ $104.00Medium
i
10/9/2019Stifel NicolausReiterated RatingHoldN/A
i
Rating by Benjamin Burnett at Stifel Nicolaus
9/30/2019Stifel NicolausInitiated CoverageHold$109.00High
i
9/18/2019William BlairReiterated RatingHoldLow
i
Rating by R. Prasad at William Blair
8/12/2019William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by R. Prasad at William Blair
8/6/2019Morgan StanleyLower Price TargetEqual Weight$143.00 ➝ $136.00Medium
i
7/19/2019GabelliReiterated RatingBuyN/A
i
Rating by Jing He at Gabelli
6/18/2019Maxim GroupUpgradeHold ➝ Buy$160.00High
i
6/17/2019BMO Capital MarketsLower Price TargetOutperform$191.00 ➝ $163.00Low
i
Rating by Matthew Luchini at BMO Capital Markets
6/14/2019Piper Jaffray CompaniesSet Price TargetHold$120.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
6/13/2019JPMorgan Chase & Co.Reiterated RatingBuy$195.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/17/2019JPMorgan Chase & Co.Set Price TargetBuy$195.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/16/2019SunTrust BanksLower Price TargetBuy$174.00Medium
i
5/15/2019WedbushDowngradeOutperform ➝ Neutral$166.00 ➝ $131.00Medium
i
Rating by D. Nierengarten at Wedbush
5/3/2019BMO Capital MarketsSet Price TargetBuy$191.00High
i
Rating by Matthew Luchini at BMO Capital Markets
5/3/2019William BlairReiterated RatingBuyMedium
i
Rating by R. Prasad at William Blair
4/23/2019William BlairReiterated RatingOutperformLow
i
Rating by R. Prasad at William Blair
3/22/2019Cantor FitzgeraldSet Price TargetHold$122.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
3/5/2019SVB LeerinkDowngradeOutperform ➝ Market PerformLow
i
Rating by M. Foroohar at SVB Leerink LLC
2/26/2019CowenInitiated CoverageOutperform$149.91High
i
Rating by Chris Shibutani at Cowen Inc
2/25/2019SunTrust BanksLower Price TargetBuy$184.00High
i
2/22/2019BMO Capital MarketsBoost Price TargetOutperform$194.00Medium
i
2/22/2019Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$134.00 ➝ $122.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
1/23/2019Canaccord GenuityReiterated RatingBuy ➝ Buy$250.00 ➝ $161.00High
i
1/11/2019OppenheimerReiterated RatingHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
12/19/2018Raymond JamesInitiated CoverageStrong-Buy ➝ Strong-Buy$165.00High
i
12/9/2018CowenReiterated RatingBuyLow
i
Rating by Chris Shibutani at Cowen Inc
12/6/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$240.00 ➝ $120.00Medium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
12/4/2018OppenheimerReiterated RatingHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/4/2018William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
12/3/2018Janney Montgomery ScottSet Price TargetOutperform ➝ Buy$170.00High
i
Rating by Yun Zhong at Janney Montgomery Scott
12/3/2018Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
12/3/2018Cantor FitzgeraldReiterated RatingHold$134.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
11/27/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/27/2018SVB LeerinkInitiated CoverageOutperform$145.00 ➝ $145.00Low
i
Rating by M. Foroohar at SVB Leerink LLC
11/14/2018Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00High
i
11/5/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$186.00 ➝ $185.00Low
i
11/5/2018WedbushLower Price TargetOutperform ➝ Outperform$204.00 ➝ $166.00Medium
i
11/5/2018Janney Montgomery ScottUpgradeNeutral ➝ Buy$170.00 ➝ $170.00Medium
i
Rating by Yun Zhong at Janney Montgomery Scott
11/4/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
11/2/2018CowenReiterated RatingBuyMedium
i
11/2/2018OppenheimerReiterated RatingHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/2/2018Cantor FitzgeraldUpgradeUnderweight ➝ Neutral$122.00 ➝ $134.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
11/1/2018Maxim GroupReiterated RatingHoldMedium
i
11/1/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
10/15/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$190.00 ➝ $186.00Low
i
9/21/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyMedium
i
9/17/2018GuggenheimInitiated CoverageNeutralMedium
i
9/5/2018Cantor FitzgeraldSet Price TargetSell$122.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
9/5/2018William BlairReiterated RatingBuyMedium
i
Rating by Raju Prasad at William Blair
8/23/2018Cantor FitzgeraldSet Price TargetSell$122.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/6/2018Maxim GroupReiterated RatingHoldLow
i
Rating by Jason McCarthy at Maxim Group
8/6/2018CowenReiterated RatingBuyLow
i
8/6/2018Cantor FitzgeraldSet Price TargetSell$122.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/3/2018SunTrust BanksReiterated RatingBuy$223.00High
i
8/3/2018BMO Capital MarketsReiterated RatingBuy$208.00High
i
Rating by Matthew Luchini at BMO Capital Markets
8/2/2018Piper Jaffray CompaniesReiterated RatingBuyMedium
i
Rating by Tyler Van Buren at Piper Jaffray Companies
7/30/2018Maxim GroupLower Price TargetHold$163.00Low
i
Rating by Jason McCarthy at Maxim Group
7/13/2018Cantor FitzgeraldSet Price TargetSell$122.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
7/12/2018GabelliInitiated CoverageBuy$239.00Low
i
Rating by J. He at Gabelli
6/19/2018Evercore ISIUpgradeIn-Line ➝ Outperform$175.00 ➝ $230.00Low
i
6/5/2018Piper Jaffray CompaniesSet Price TargetBuy$240.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
6/4/2018Cantor FitzgeraldUpgradeUnderweight ➝ OverweightLow
i
Rating by E. Piros at Cantor Fitzgerald
6/4/2018CowenReiterated RatingBuyHigh
i
6/3/2018Cantor FitzgeraldSet Price TargetSell$122.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Buy$240.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/16/2018Cantor FitzgeraldReiterated RatingUnderweightLow
i
Rating by E. Piros at Cantor Fitzgerald
5/10/2018Cantor FitzgeraldReiterated RatingSell$122.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
5/7/2018Sanford C. BernsteinReiterated RatingMarket Perform$211.00Low
i
Rating by Vincent Chen at Sanford C. Bernstein
5/3/2018Maxim GroupSet Price TargetHold$200.00High
i
Rating by Jason McCarthy at Maxim Group
5/3/2018BMO Capital MarketsLower Price TargetOutperform ➝ Buy$222.00 ➝ $216.00High
i
Rating by Matthew Luchini at BMO Capital Markets
5/3/2018BTIG ResearchReiterated RatingBuyHigh
i
4/19/2018SunTrust BanksBoost Price TargetBuy$232.00High
i
3/28/2018Canaccord GenuityReiterated RatingBuyLow
i
Rating by John Newman at Canaccord Genuity
3/21/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$152.00 ➝ $209.00High
i
3/16/2018William BlairReiterated RatingBuyMedium
i
Rating by Raju Prasad at William Blair
3/16/2018UBS GroupInitiated CoverageSellHigh
i
3/14/2018Janney Montgomery ScottInitiated CoverageNeutral ➝ Neutral$220.00Medium
i
3/13/2018Canaccord GenuityReiterated RatingBuy$250.00Low
i
Rating by John Newman at Canaccord Genuity
3/8/2018BTIG ResearchBoost Price TargetBuy$250.00Medium
i
3/5/2018William BlairInitiated CoverageOutperform ➝ Outperform$206.10 ➝ $242.00High
i
Rating by Raju Prasad at William Blair
2/26/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$151.00 ➝ $152.00Medium
i
2/22/2018Maxim GroupReiterated RatingHold$200.00Medium
i
Rating by Jason McCarthy at Maxim Group
2/22/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$185.00 ➝ $218.00Medium
i
2/22/2018BMO Capital MarketsSet Price TargetOutperform ➝ Buy$215.00 ➝ $222.00High
i
Rating by Matthew Luchini at BMO Capital Markets
2/22/2018Sanford C. BernsteinReiterated RatingHold$153.00 ➝ $211.00High
i
2/22/2018Cantor FitzgeraldLower Price TargetUnderweight$122.00 ➝ $113.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/21/2018Cantor FitzgeraldReiterated RatingUnderweight ➝ Sell$122.00 ➝ $113.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/1/2018Canaccord GenuityReiterated RatingBuy$250.00High
i
Rating by John Newman at Canaccord Genuity
1/25/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$162.00 ➝ $194.00Low
i
Rating by M. Schmidt at SVB Leerink LLC
1/9/2018OppenheimerReiterated RatingHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/21/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformHigh
i
12/20/2017OppenheimerInitiated CoverageMarket PerformLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/13/2017Maxim GroupDowngradeBuy ➝ Hold$200.00Medium
i
Rating by Jason McCarthy at Maxim Group
12/13/2017BarclaysReiterated RatingOverweight ➝ Overweight$162.00 ➝ $209.00High
i
12/12/2017SunTrust BanksBoost Price TargetBuy$223.00High
i
12/12/2017Wells Fargo & CompanyReiterated RatingOutperform$190.00 ➝ $242.00High
i
12/11/2017BMO Capital MarketsSet Price TargetBuy$215.00High
i
Rating by Matthew Luchini at BMO Capital Markets
12/11/2017Jefferies Financial GroupUpgradeHold ➝ Buy$130.00 ➝ $211.00High
i
12/11/2017Cantor FitzgeraldSet Price TargetUnderweight ➝ Underweight$58.00 ➝ $113.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
12/5/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$202.00Low
i
11/30/2017Maxim GroupBoost Price TargetBuy ➝ Buy$170.00 ➝ $200.00High
i
Rating by Jason McCarthy at Maxim Group
11/17/2017Maxim GroupSet Price TargetBuy$170.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/3/2017SunTrust BanksBoost Price TargetBuy ➝ Buy$108.00 ➝ $163.00N/A
i
11/3/2017Jefferies Financial GroupReiterated RatingHold$130.00N/A
i
11/3/2017Morgan StanleyUpgradeUnderweight ➝ Equal WeightN/A
i
11/2/2017BarclaysBoost Price TargetOverweight$151.00 ➝ $162.00N/A
i
11/2/2017Maxim GroupReiterated RatingBuy$170.00N/A
i
Rating by Jason McCarthy at Maxim Group
11/2/2017WedbushReiterated RatingOutperform$135.00 ➝ $174.00N/A
i
11/2/2017BTIG ResearchUpgradeNeutral ➝ Buy$177.00N/A
i
11/1/2017SVB LeerinkReiterated RatingOutperform$145.00 ➝ $162.00N/A
i
11/1/2017Cantor FitzgeraldReiterated RatingSell$39.00 ➝ $58.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
10/30/2017BMO Capital MarketsBoost Price TargetBuy$134.00 ➝ $162.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
10/16/2017Evercore ISIUpgradeIn-Line ➝ Outperform$102.00N/A
i
10/11/2017Jefferies Financial GroupReiterated RatingBuy ➝ Hold$126.00N/A
i
10/9/2017Maxim GroupReiterated RatingBuy ➝ Buy$100.00 ➝ $170.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/6/2017SVB LeerinkReiterated RatingOutperform$120.00 ➝ $145.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$186.00N/A
i
10/2/2017Morgan StanleyDowngradeEqual Weight ➝ Underweight$105.00High
i
9/30/2017SVB LeerinkReiterated RatingOutperform$120.00High
i
9/28/2017Cantor FitzgeraldReiterated RatingSell$39.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/6/2017BarclaysInitiated CoverageOverweight$151.00Low
i
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$134.00 ➝ $158.00Medium
i
9/1/2017WedbushReiterated RatingOutperform$121.00 ➝ $135.00High
i
8/31/2017CowenReiterated RatingOutperformHigh
i
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$102.00High
i
8/11/2017Jefferies Financial GroupReiterated RatingBuy$88.00Medium
i
8/9/2017Morgan StanleyReiterated RatingHoldHigh
i
8/7/2017Morgan StanleyBoost Price TargetEqual ➝ Equal Weight$103.00 ➝ $105.00Medium
i
8/4/2017BMO Capital MarketsReiterated RatingBuy$108.00Medium
i
Rating by Matthew Luchini at BMO Capital Markets
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$109.00High
i
7/24/2017Cantor FitzgeraldReiterated RatingSell$39.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/10/2017Morgan StanleyReiterated RatingEqual Weight$105.00 ➝ $103.00Low
i
7/6/2017Jefferies Financial GroupReiterated RatingBuyLow
i
6/30/2017BTIG ResearchDowngradeBuy ➝ Neutral$37.05 ➝ $108.25Medium
i
6/28/2017BTIG ResearchReiterated RatingBuy ➝ Buy$112.00High
i
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
6/24/2017Cantor FitzgeraldSet Price TargetSell$37.00 ➝ $39.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
6/23/2017CowenReiterated RatingBuyLow
i
6/23/2017WedbushReiterated RatingOutperform$121.00 ➝ $100.00Low
i
6/16/2017Standpoint ResearchReiterated RatingBuy ➝ Reduce$110.00Low
i
6/14/2017Morgan StanleyReiterated RatingEqual Weight$91.00 ➝ $105.00Low
i
6/9/2017CowenReiterated RatingOutperformLow
i
6/7/2017Janney Montgomery ScottBoost Price TargetNeutral ➝ Buy$81.00 ➝ $125.00High
i
6/6/2017WedbushReiterated RatingOutperformHigh
i
6/6/2017BMO Capital MarketsReiterated RatingBuy$108.00High
i
6/5/2017BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$61.00 ➝ $108.00High
i
6/5/2017Bank of AmericaReiterated RatingHold$95.00High
i
6/5/2017Cantor FitzgeraldSet Price TargetSell$37.00High
i
6/2/2017Maxim GroupUpgradeHold ➝ Buy$100.00High
i
Rating by Jason McCarthy at Maxim Group
6/1/2017BTIG ResearchReiterated RatingBuy$112.00High
i
5/30/2017Standpoint ResearchInitiated CoverageBuy ➝ Buy$110.00Low
i
5/15/2017Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason McCarthy at Maxim Group
5/8/2017Morgan StanleyBoost Price TargetEqual Weight$87.00 ➝ $91.00Medium
i
5/5/2017Maxim GroupReiterated RatingHoldHigh
i
Rating by Jason McCarthy at Maxim Group
5/1/2017BTIG ResearchReiterated RatingBuyMedium
i
3/24/2017Jefferies Financial GroupReiterated RatingBuy$88.00High
i
Rating by Gena Wang at Jefferies Financial Group Inc.
3/1/2017Morgan StanleyBoost Price TargetEqual Weight$58.00 ➝ $87.00N/A
i
2/27/2017Maxim GroupDowngradeBuy ➝ Hold$87.00N/A
i
Rating by Jason McCarthy at Maxim Group
2/23/2017Roth CapitalSet Price TargetHold$71.00N/A
i
Rating by Mark Breidenbach at Roth Capital
2/23/2017BMO Capital MarketsReiterated RatingMarket Perform$83.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
2/6/2017Roth CapitalReiterated RatingBuy ➝ Neutral$87.00 ➝ $71.00N/A
i
Rating by Mark Breidenbach at Roth Capital
2/3/2017Maxim GroupSet Price TargetBuy$87.00N/A
i
Rating by Jason McCarthy at Maxim Group
1/10/2017Jefferies Financial GroupReiterated RatingBuy$88.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
12/15/2016Roth CapitalReiterated RatingBuy$87.00N/A
i
Rating by Mark Breidenbach at Roth Capital
12/13/2016Maxim GroupReiterated RatingBuy$87.00N/A
i
Rating by Jason McCarthy at Maxim Group
12/12/2016Jefferies Financial GroupSet Price TargetBuy$88.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
12/10/2016Cantor FitzgeraldReiterated RatingSellN/A
i
Rating by E. Piros at Cantor Fitzgerald
12/7/2016JPMorgan Chase & Co.Reiterated RatingBuy$120.00N/A
i
12/4/2016Bank of AmericaReiterated RatingNeutral$68.00N/A
i
12/1/2016SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $85.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
12/1/2016WedbushReiterated RatingOutperform$95.00N/A
i
12/1/2016BMO Capital MarketsSet Price TargetHold$61.00 ➝ $83.00N/A
i
Rating by Matthew Luchini at BMO Capital Markets
12/1/2016Jefferies Financial GroupSet Price TargetBuy$80.00 ➝ $88.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
12/1/2016Roth CapitalSet Price TargetBuy$87.00N/A
i
Rating by Mark Breidenbach at Roth Capital
12/1/2016Maxim GroupBoost Price TargetBuy$57.00 ➝ $87.00N/A
i
Rating by Jason McCarthy at Maxim Group
12/1/2016Cantor FitzgeraldReiterated RatingSell$37.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
12/1/2016BTIG ResearchReiterated RatingBuy$83.00N/A
i
Rating by Dane Leone at BTIG Research
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/24/2016Janney Montgomery ScottReiterated RatingBuyN/A
i
Rating by Debjit Chattopadhyay at Janney Montgomery Scott
11/24/2016Jefferies Financial GroupSet Price TargetBuy$80.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/23/2016WedbushReiterated RatingOutperform$95.00N/A
i
11/10/2016BMO Capital MarketsInitiated CoverageMarket Perform$61.00N/A
i
11/7/2016BTIG ResearchReiterated RatingBuy$83.00N/A
i
Rating by Dane Leone at BTIG Research
11/7/2016SVB LeerinkReiterated RatingOutperform$80.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
11/7/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
11/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/4/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
11/3/2016WedbushReiterated RatingOutperform$95.00 ➝ $117.00N/A
i
11/3/2016Cantor FitzgeraldReiterated RatingSell$37.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
10/25/2016Piper Jaffray CompaniesSet Price TargetBuy$95.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
10/17/2016CowenReiterated RatingOutperformN/A
i
10/15/2016Jefferies Financial GroupSet Price TargetBuy$80.00N/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
10/15/2016The Goldman Sachs GroupReiterated RatingBuy$135.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
10/15/2016BTIG ResearchReiterated RatingBuy$72.00 ➝ $83.00N/A
i
Rating by Dane Leone at BTIG Research
10/14/2016SVB LeerinkBoost Price TargetOutperform$67.00 ➝ $80.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
10/14/2016WedbushReiterated RatingOutperform$117.00N/A
i
10/14/2016Cantor FitzgeraldDowngradeHold ➝ Sell$65.24 ➝ $37.00N/A
i
Rating by E. Piros at Cantor Fitzgerald
10/14/2016SunTrust BanksReiterated RatingBuyN/A
i
10/13/2016Piper Jaffray CompaniesSet Price TargetBuy$95.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
10/3/2016WedbushReiterated RatingOutperform$117.00N/A
i
9/30/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
9/29/2016Maxim GroupSet Price TargetBuy$85.00 ➝ $100.00N/A
i
Rating by jason mccarthy at Maxim Group
9/23/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
9/22/2016Maxim GroupSet Price TargetBuy$85.00N/A
i
Rating by jason mccarthy at Maxim Group
9/22/2016Roth CapitalInitiated CoverageBuy$87.00N/A
i
Rating by M. Breidenbach at Roth Capital
9/15/2016The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$135.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
9/12/2016Maxim GroupReiterated RatingBuy$85.00N/A
i
Rating by Jason McCarthy at Maxim Group
9/11/2016BTIG ResearchReiterated RatingBuy$72.00N/A
i
Rating by Dane Leone at BTIG Research
9/9/2016CowenReiterated RatingOutperformN/A
i
9/9/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Michael Schmidt at SVB Leerink LLC
9/8/2016Piper Jaffray CompaniesSet Price TargetBuy$95.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
9/8/2016WedbushReiterated RatingOutperform$117.00N/A
i
9/8/2016The Goldman Sachs GroupReiterated RatingBuy$135.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/18/2016The Goldman Sachs GroupReiterated RatingBuy$135.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/18/2016Piper Jaffray CompaniesReiterated RatingOverweight$117.00 ➝ $95.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/4/2016SVB LeerinkReiterated RatingOutperform$67.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/4/2016Maxim GroupReiterated RatingBuy$105.00 ➝ $85.00N/A
i
Rating by Jason McCarthy at Maxim Group
8/3/2016WedbushReiterated RatingOutperform$117.00N/A
i
7/14/2016Jefferies Financial GroupReiterated RatingPositive$80.00N/A
i
7/8/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
6/29/2016BTIG ResearchReiterated RatingBuy$72.00N/A
i
Rating by Dane Leone at BTIG Research
(Data available from 6/16/2016 forward)
bluebird bio logo
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent Ã-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $32.78
$31.94
$33.23

50 Day Range

MA: $30.31
$27.86
$34.10

52 Week Range

Now: $32.78
$24.24
$68.39

Volume

869,499 shs

Average Volume

1,816,218 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Canaccord Genuity, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, Wedbush, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

15 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $60.53, suggesting a possible upside of 84.7%. Royal Bank of Canada has the highest price target set, predicting BLUE will reach $93.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $27.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 12 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is 339-499-9300 and its investor relations email address is [email protected] The official website for bluebird bio is www.bluebirdbio.com.